Immunotech Biopharm Ltd Stock Forecast for 2023 - 2025 - 2030
Updated on 09/25/2023
Immunotech Biopharm Ltd Fair Value Forecast for 2023 - 2025 - 2030
In the last two years, Immunotech Biopharm Ltd's Price has grown from HK$0.00 to HK$0.00 – a 100.00% increase. Next year, analysts are expecting Fair Value to reach HK$0.00 – an increase of 100.00%. Over the next nine years, the forecast is for Fair Value to grow by 100.00%.
Immunotech Biopharm Ltd Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last year, Immunotech Biopharm Ltd's Free Cash Flow has grown, rising from HK$-109.23M to HK$-288.71M – a growth of 164.31%. According to 0 prominent analysts, Immunotech Biopharm Ltd's Free Cash Flow will fall by 62.17% in the next year, reaching HK$-109.22M. By 2030, professionals believe that Immunotech Biopharm Ltd's Free Cash Flow will decrease by 13.41%, reaching HK$-250.00M – a concerning trend for the company.
Immunotech Biopharm Ltd Net Income Forecast for 2023 - 2025 - 2030
In the last two years, Immunotech Biopharm Ltd's Net Income has grown by 225.57%, rising from HK$-108.80M to HK$-354.22M. For the next year, 0 analysts project Immunotech Biopharm Ltd's Net Income to drop by 9.11%, reaching HK$-321.96M. By 2030, professionals believe that Immunotech Biopharm Ltd's Net Income will decrease by 7.47%, reaching HK$-327.77M – a concerning trend for the company.
Immunotech Biopharm Ltd EBITDA Forecast for 2023 - 2025 - 2030
Immunotech Biopharm Ltd's EBITDA has grown In the last two years, rising from HK$-86.79M to HK$-331.41M – a growth of 281.85%. In the following year, 0 experts forecast Immunotech Biopharm Ltd's EBITDA will decrease by 24.15%, to HK$-251.37M. In 2030, professionals predict that Immunotech Biopharm Ltd's EBITDA will decrease by 19.75%, to HK$-265.96M.
Immunotech Biopharm Ltd EBIT Forecast for 2023 - 2025 - 2030
Immunotech Biopharm Ltd's EBIT has seen impressive growth In the last two years, rising from HK$-97.73M to HK$-345.15M – a growth of 253.17%. According to 0 major analysts, Immunotech Biopharm Ltd's EBIT will fall by 23.47% in the next year, reaching HK$-264.14M. Professionals believe that By 2030, Immunotech Biopharm Ltd's EBIT will fall to HK$-278.67M– a 19.26% decrease from its current value.
Immunotech Biopharm Ltd EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last two years, Immunotech Biopharm Ltd's EPS has grown from HK$-0.29 to HK$-0.69 – a 137.93% increase. Next year, analysts are expecting EPS to reach HK$-0.73 – an increase of 5.42%. Over the next nine years, the forecast is for EPS to grow by 6.37%.